On Friday, Cytokinetics Inc (NASDAQ: CYTK) was 4.25% up from the session before settling in for the closing price of $60.77. A 52-week range for CYTK has been $29.31 – $69.33.
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.02%. When this article was written, the company’s average yearly earnings per share was at -18.71%. With a float of $119.91 million, this company’s outstanding shares have now reached $122.12 million.
Cytokinetics Inc (CYTK) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytokinetics Inc stocks. The insider ownership of Cytokinetics Inc is 1.98%, while institutional ownership is 115.57%. The most recent insider transaction that took place on Dec 08 ’25, was worth 68,730. In this transaction EVP, Chief Commercial Officer of this company sold 1,042 shares at a rate of $65.96, taking the stock ownership to the 50,660 shares. Before that another transaction happened on Dec 05 ’25, when Company’s EVP, Chief Commercial Officer sold 52,486 for $65.95, making the entire transaction worth $3,461,452. This insider now owns 50,660 shares in total.
Cytokinetics Inc (CYTK) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.26 earnings per share (EPS) during the time that was less than consensus figure (set at -1.17) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.57% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
You can see what Cytokinetics Inc (CYTK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 88.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.31, a number that is poised to hit -1.40 in the next quarter and is forecasted to reach -5.61 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Looking closely at Cytokinetics Inc (NASDAQ: CYTK), its last 5-days average volume was 1.76 million, which is a drop from its year-to-date volume of 1.9 million. As of the previous 9 days, the stock’s Stochastic %D was 23.29%.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 83.59%, which indicates a significant increase from 38.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.45 in the past 14 days, which was higher than the 2.33 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.35, while its 200-day Moving Average is $44.94. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $64.62. Second resistance stands at $65.89. The third major resistance level sits at $67.97. If the price goes on to break the first support level at $61.26, it is likely to go to the next support level at $59.18. Now, if the price goes above the second support level, the third support stands at $57.91.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are 122,265K outstanding shares of the company, which has a market capitalization of 7.75 billion. As of now, sales total 18,470 K while income totals -589,530 K. Its latest quarter income was 1,940 K while its last quarter net income were -306,180 K.
